ERG Developments unveils 27-feddan Linwood project in New Cairo
Egypt - ERG Developments has officially launched its Linwood project in New Cairo, a 27-feddan residential development designed by renowned architect Raef Fahmy, according to the company's founder, Mohamed Rizk.
Located along the Youssef El-Sebaei Axis, just north of Al-Rehab City, Linwood offers a limited selection of villas and townhouses featuring modern designs and cutting-edge smart technologies.
The project is strategically positioned in one of New Cairo's most rapidly developing areas, known for its proximity to key urban centers, established residential communities, and essential amenities—making it a prime location for future residents.
Linwood sets a new benchmark for residential compounds in Egypt, reflecting ERG Developments' commitment to creating high-quality living spaces in prime locations.
The project expands on the success of the Eelaf project, which offers residential apartments ranging from one to four rooms, further diversifying the company's portfolio and enhancing the variety of housing options available to potential homeowners.
Linwood exemplifies ERG Developments' approach to identifying and developing locations that align with the evolving needs of its clients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
4 minutes ago
- Daily Mail
Tottenham reveal why they sacked Ange Postecoglou in lengthy club statement
Tottenham Hotspur have issued a 368-word club statement in an attempt to justify the sacking of manager Ange Postecoglou. Spurs confirmed on Friday afternoon that Postecoglou would not be returning for a third campaign in charge following his post-season holiday. His dismissal was announced just 16 days after he oversaw a famous victory over Manchester United in the UEFA Europa League final. That win sealed a place in next season's Champions League. However, as mentioned in Friday's statement, Postecoglou also oversaw the club's worst ever Premier League season, which resulted in a 17th-place finish following 22 defeats. 'Following a review of performances and after significant reflection, the Club can announce that Ange Postecoglou has been relieved of his duties,' the statement began. 'Ange joined us from Celtic in the summer of 2023 and oversaw a period of change on the pitch, returning us to the attacking brand of football that has traditionally been associated with the Club, while writing a new chapter in our history by leading us to UEFA Europa League glory in Bilbao last month - an achievement that will live with us all forever. 'We are extremely grateful to Ange for his commitment and contribution during his two years at the Club. Ange will always be remembered as only the third manager in our history to deliver a European trophy, alongside legendary figures Bill Nicholson and Keith Burkinshaw. 'However, the Board has unanimously concluded that it is in the best interests of the Club for a change to take place. Following a positive start in the 2023/24 Premier League (PL) season, we recorded 78 points from the last 66 PL games. This culminated in our worst-ever PL finish last season. At times there were extenuating circumstances - injuries and then a decision to prioritise our European campaign. Whilst winning the Europa League this season ranks as one of the Club's greatest moments, we cannot base our decision on emotions aligned to this triumph. 'It is crucial that we are able to compete on multiple fronts and believe a change of approach will give us the strongest chance for the coming season and beyond. This has been one of the toughest decisions we have had to make and is not a decision that we have taken lightly, nor one we have rushed to conclude. We have made what we believe is the right decision to give us the best chance of success going forward, not the easy decision. 'We have a talented, young squad and Ange has given us a great platform to build upon. We should like to express our gratitude to him. We wish him well for the future - he will always be welcome back at our home. 'News on the appointment of a new Head Coach will be announced in due course.' Tottenham's statement explaining the sacking of Postecoglou was significantly longer than that granted to his predecessors. Spurs used just 111 words to in their official statement when Antonio Conte left the club, having published a 122-word message to signal the end of the Jose Mourinho era.
Business Wire
5 minutes ago
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
BBC News
5 minutes ago
- BBC News
Murder arrest after woman found dead in flat in Derby
A man has been arrested on suspicion of murder after a 47-year-old woman was found dead in a were called to the property in Ashe Place, in Normanton, Derby, at about 11:30 BST on investigation has been launched into the cause of her death, police force said this was believed to be an isolated incident, adding a 63-year-old suspect remained in police custody. Ch Insp Lauren Woods said: "As there has been an increased police presence in the area recently we are aware that this may be causing the community concern. "We would like to provide reassurance that this incident is believed to be isolated and took place inside a property."Please feel free to approach them with any information you may have that could help our investigation."
